Wave Life Sciences Ltd.

Good morning and welcome to the Wave Life Sciences second quarter 2022 financial results in the business update conference call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded and webcast. I'll now turn the call over to Kate Rausch, VP of Investor Relations and Corporate Affairs at Wave Life Sciences. Please go ahead.

Thank you, Operator. Good morning, and thank you for joining us today to discuss our recent business progress and review Wave's second quarter 2022 financial results. Joining me today are Dr. Paul Bologno, President and Chief Executive Officer, Dr. Mike Panzera, Chief Medical Officer and Head of Therapeutic Discovery and Development, Dr. Chandra Varghese, Chief Technology Officer and Head of Platform Discovery Sciences, and Kyle Moran, Chief Financial Officer. The press release issued this morning and the slide presentation to accompany this webcast are available on the Investors section of our website, www.wavelifesciences.com. Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the test release issued today and in our SEC filings, including our annual report on Form 10-K for the year ended December 31, 2021, and our quarterly report on Form 10-Q for the quarter ended June 30, 2022. We undertake no obligation to update or revise any forward-looking statements for any reason. I'd now like to turn the call over to Paul. Paul?

Thanks, Kate. Good morning, and thank you all for joining us. In the second quarter, we continue to make meaningful progress both on our therapeutic program and our platform. I will start with some recent highlights. I'll then turn the call over to Mike, who will provide updates on our innovative pipeline Chandra will then share some examples of how we continue to expand the addressable biological targets with our unique RNA-based editing platform. And finally, Kyle will discuss our financials. I'm excited to begin today's call by announcing the selection of WVE-006 as our first RNA editing development candidate for alpha-1 antitrypsin deficiency, or AATD. We're also announcing that we expect to initiate clinical development of 006 in 2023. O6 is a first-in-class RNA editing candidate and the most advanced therapeutic program currently in development to harness an endogenous enzyme for editing. There are approximately 200,000 people carrying homozygous disease mutations in the U.S. and Europe, and WVE-006 has the potential to transform how these patients are treated. Demonstrating clinical proof of concept in AETD with 006 would serve to de-risk RNA editing for additional monogenic diseases as well as open opportunities to address larger disease implications through modulation of proteins such as disruption of protein-protein interactions and upregulation. Continued investment in our PRISM platform has positioned us as leaders in oligonucleotide innovation, and we continue to be encouraged by the translation of our guide strands across multiple modalities. Earlier this year, we shared positive target engagement data from our ongoing focused C9 clinical trials in C9 ALS and FTD, which demonstrated how our preclinical data are now translating in patients. New pharmacokinetic data from our ongoing DMD and HC studies, which Mike will share today, further support this clinical translation of differentiated pharmacology. We remain on track to share data from all three of our clinical studies this year. In June, we completed a successful follow-on offering, which put WAVE in a strong, well-capitalized position entering the second half of 2022. We continue to execute on multiple pillars of value creation, including delivering clinical updates and rapidly advancing our novel RNA-based editing pipeline led by WVE-006. We also continue to advance discussions with potential strategic partners who share our vision for broad applications of WAVE platform and support expansion of our pipeline while unlocking value in GMP manufacturing. I'll now turn the call over to Mike to provide an update on our pipeline.